Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$9.99 - $18.71 $9.81 Million - $18.4 Million
-982,414 Reduced 23.5%
3,197,810 $59.3 Million
Q2 2023

Aug 14, 2023

BUY
$9.17 - $19.29 $10.3 Million - $21.7 Million
1,125,714 Added 36.85%
4,180,224 $46.2 Million
Q1 2023

May 15, 2023

SELL
$12.53 - $21.71 $1.52 Million - $2.64 Million
-121,415 Reduced 3.82%
3,054,510 $41 Million
Q4 2022

Feb 14, 2023

BUY
$11.61 - $16.11 $1.44 Million - $2 Million
124,341 Added 4.07%
3,175,925 $39.3 Million
Q3 2022

Nov 15, 2022

SELL
$12.21 - $19.7 $5.19 Million - $8.37 Million
-425,048 Reduced 12.23%
3,051,584 $42.6 Million
Q2 2022

Aug 15, 2022

BUY
$11.23 - $19.59 $2.86 Million - $4.99 Million
254,800 Added 7.91%
3,476,632 $48 Million
Q1 2022

May 16, 2022

SELL
$13.37 - $17.79 $433,642 - $577,000
-32,434 Reduced 1.0%
3,221,832 $52.4 Million
Q4 2021

Feb 14, 2022

BUY
$14.28 - $19.53 $1.55 Million - $2.13 Million
108,825 Added 3.46%
3,254,266 $53 Million
Q3 2021

Nov 15, 2021

BUY
$12.99 - $20.47 $6.35 Million - $10 Million
488,857 Added 18.4%
3,145,441 $46.7 Million
Q2 2021

Aug 16, 2021

SELL
$15.46 - $24.5 $2.76 Million - $4.38 Million
-178,758 Reduced 6.3%
2,656,584 $53.1 Million
Q1 2021

May 17, 2021

BUY
$19.33 - $37.75 $5.5 Million - $10.7 Million
284,592 Added 11.16%
2,835,342 $65.4 Million
Q4 2020

Feb 16, 2021

BUY
$24.48 - $42.47 $21.1 Million - $36.6 Million
860,697 Added 50.93%
2,550,750 $63 Million
Q3 2020

Nov 10, 2020

BUY
$39.09 - $53.44 $17 Million - $23.3 Million
435,702 Added 34.74%
1,690,053 $70.1 Million
Q2 2020

Aug 14, 2020

BUY
$46.7 - $92.04 $4.6 Million - $9.07 Million
98,552 Added 8.53%
1,254,351 $60.1 Million
Q1 2020

May 11, 2020

BUY
$48.35 - $118.68 $55.9 Million - $137 Million
1,155,799 New
1,155,799 $72.8 Million

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.